It was shown that gefitinib is useful as a second-line treatment following platinum-based chemotherapy for non-small cell lung cancer (NSCLC) but failed to exert any additional effect as a first-line treatment. Erlotinib was also found to be effective in patients with EGFR mutation tumors....
availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has provided oncologists with a potentially confusing choice for the treatment of EGFR mutation-positive non-small-cell lung cancer. ...
Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer. 2015;121(15):2570-2577. doi:10.1002/cncr.29397PubMedGoogle ScholarCrossref 19. Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in pretreated T790M-...
Aim: The progression free survival of non-small cell lung cancer (NSCLC) patients has been doubled over the last years, but still single epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) lead to incomplete responses. Compensatory signaling pathways are activated upon single ...
Conclusion: Patients in their 70s and 80s with non-small cell lung cancer were relatively frequently EGFR gene-positive. To avoid missing out on treatment opportunities, EGFR gene testing should also be performed on patients in this age group.Anticancer ResearchYOSUKE MAEZAWAMANATO TAGUCHITAKESHI ...
P2.03-047 The Main Treatment Failure Pattern for Completely Resected Stage II–IIIA (N1–N2) EGFR-Mutation Positive Lung Cancerdoi:10.1016/j.jtho.2017.09.1298Xu, S.Zhong, W.Zhang, Y.Mao, W.Wu, L.Shen, Y.Liu, Y.Chen, C.Cheng, Y....
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines Therapies that target the EGF receptor (EGER), such as gefitinib (IRESSA), are effective in a subset of patients with advanced non-small cell lung cancer (... J.,A.,Engelman,.....
EGFR overexpression is frequently observed in various human cancers, including head and neck, colorectal, lung, breast, prostate, kidney, pancreatic, ovarian, brain, and bladder cancers1. Two pharmacological approaches for cancer treatment have been used to block EGFR: (1) monoclonal antibodies, ...
Abstract A250: ABT-414: An anti-EGFR antibody-drug conjugate as a potential therapeutic for the treatment of patients with squamous cell tumors. ABT-414 is an antibody-drug conjugate (ADC) comprised of an anti-EGFR antibody (ABT-806) conjugated to the potent cytotoxic monomethylauristatin F. ...
Nivolumab as first line monotherapy for advanced non-small cell lung cancer: could we replace first line chemotherapy with immunotherapy? Transl Lung Cancer Res. 2014;3(6):400–2. 51. Tsai K, Daud A. Nivolumab plus ipilimumab in the treatment of advanced melanoma. J Hematol Oncol. 2015;8...